How can we avert hepatic vascular complications in SMANCS therapy for hepatocellular carcinoma?
Okada
S
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001157:Arterial Occlusive Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D006499:Hepatic Artery; D006801:Humans; D015994:Incidence; D007269:Injections, Intra-Arterial / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008299:Maleic Anhydrides / Q000008:administration & dosage / Q000009:adverse effects*; D011137:Polystyrenes / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D009353:Zinostatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D009353:Zinostatin